All News

Single-dose URO-902 appeared to be safe and effective in treating women with overactive bladder and urge urinary incontinence, according to the final analysis of a phase 2a trial.

The patients’ preference for vibegron could be depending on the better efficacy for urgency incontinence, said Naoki Wada, PhD.

“We looked at safety issues within 12 months after the implantation, and they were minor—some pain problems, some wound-healing problems, but no serious adverse events,” said John Heesakkers, MD, PhD.

The results may help guide the decision between a partial and radical nephrectomy in patients with stage T1b to T2 renal cell carcinoma.

“What we found is that hypertension is an independent risk factor for worsened survival outcomes and mortality outcomes across the board on multivariable and Kaplan Meier analysis,” said Sohail Dhanji, MD.

The results provide further evidence of the “obesity paradox” in patients with renal cell carcinoma.

Investigators retrospectively studied patients with Peyronie disease and diabetes mellitus between 2007 and 2022.

The 3- and 5-year MFS rates for those treated with enzalutamide plus leuprolide were 92.9% and 87.3%, respectively, compared with 83.5% and 71.4% for those given leuprolide alone.

The median time to PSA0.2 was 3.5 months in the apalutamide group, 4.4 months in the enzalutamide cohort, and 7.1 months in the abiraterone acetate group.

The overall survival benefit of darolutamide in the North American population as a whole was also specifically observed in Black/African American patients.

Irrespective of response to first-line platinum-based chemotherapy, frontline maintenance therapy with avelumab plus best supportive care (BSC), compared with BSC alone, prolonged overall and progression-free survival in patients with advanced urothelial carcinoma.

“The benefits of FAP-PET imaging include the higher specificity compared to conventional imaging. There's also the potential for upstaging,” said Domenique Escobar, MD.

"Patients with a prior BPH procedure were on average older than our HoLEP controls; however, there were no other differences in preoperative patient characteristics or postoperative functional outcomes," said Nicholas S. Dean, MD.

"Dose reduction for patients with small body size may alleviate skin AEs without sacrificing oncological outcomes,” said Kyo Togashi.

Clinical progression-free survival following the first cycle of radioligand therapy was 6.3 months, and overall survival following the first cycle was 21.4 months.

A database analysis of patients who participated in the STAMPEDE trial showed that zoledronic acid can significantly lower the risk of fracture in patients with with metastatic hormone-sensitive prostate cancer starting long-term ADT.

The study is exploring the investigational N-terminal domain androgen receptor inhibitor EPI-7386 in combination with either apalutamide or abiraterone acetate.

“I think we really hit upon how we work closely together in renal cell cancer—urothelial cancers in particular,” says Joelle Hamilton, MD.

"Men's health, as a sort of separate discipline or a sub discipline within urology, is definitely growing," says Andrew Y. Sun, MD.

The guideline updates span non-metastatic upper tract urothelial carcinoma, female stress urinary incontinence, urethral stricture disease, and prostate cancer.

Roger Li, MD, highlights 4 studies in bladder cancer being presented at the 2023 American Urological Association Annual Meeting.

"This is something [that is] a lot easier for the patient, it's a lot less costly to the health care system to stay out of the operating room, and it's a lot quicker for me," says Howard B. Goldman, MD.

Physicians are now using the AI-powered Unfold AI platform to work with patients on treatment selection and establishing an optimal overall management plan.

“Our results indicate that avoiding unhealthy dietary habits could be the best nutritional strategy to prevent aggressive prostate cancer,” says Adela Castelló-Pastor, PhD.

“I think being savvy about how you deal with BCG supply on the administrative side is important,” says Suzanne B. Merrill, MD, FACS.

The designation is for patients with mCRPC who have progressed on an androgen receptor pathway inhibitor and are not eligible for or decline to receive chemotherapy.

"At the end [of my talk], I really wanted to focus on how Specialty Networks could partner with us," says Jannah H. Thompson, MD, FPMRS.

This marks the first worldwide approval for the niraparib/abiraterone dual-action tablet.